NCT03319459 - FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

May 29, 2020

Study Completion Date

December 15, 2020

Conditions

HER2 Positive Gastric CancerColorectal CancerHead and Neck Squamous Cell CarcinomaEGFR Positive Solid TumorAdvanced Solid TumorsHER2-positive Breast CancerHepatocellular CarcinomaNon Small Cell Lung CancerRenal Cell CarcinomaPancreatic CancerMelanoma

Interventions

DRUG

FATE-NK100

FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity

DRUG

Cetuximab

Epidermal growth factor receptor inhibitor antineoplastic agent

DRUG

Trastuzumab

HER2/neu receptor inhibitor

Trial Locations (4)

43210

The Ohio State University James Cancer Hospital, Columbus

55455

University of Minnesota, Minneapolis

75246

Baylor Scott & White Research Institute, Dallas

92037

UCSD Moores Cancer Center, San Diego